Pfizer’s Celebrex Gets Timely Boost From NIH Alzheimer’s Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Celecoxib shows no increased cardiovascular risk in patients taking the drug for up to three years in an Alzheimer’s prevention study. NIH halts all treatment in the trial due to a naproxen safety signal and difficulty getting patients to use celecoxib following negative safety data in a colon polyp study.